trending Market Intelligence /marketintelligence/en/news-insights/trending/ixnzf4xjn8unpk4pdcuzdw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Nymox prostate cancer drug helps delay disease progression in mid-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Nymox prostate cancer drug helps delay disease progression in mid-stage study

Nymox Pharmaceutical Corp. said its fexapotide triflutate injection helped reduce the risk of disease progression among patients with prostate cancer in a mid-stage study.

The phase 2b study evaluated fexapotide triflutate in 2.5-milligram and 15-milligram doses to treat 146 patients with low grade localized prostate cancer and had Gleason grades of 3+3 or lower. The Gleason score is a grading system used to determine how aggressive the prostate cancer is.

In localized prostate cancer, the cancer is contained within the prostate gland and has not spread to other parts of the body. According to Prostate Cancer U.K., localized prostate cancer often grows slowly or may not grow at all, with a low risk of it spreading.

After 78 months of treatment, patients who received the 15-mg fexapotide experienced a 73% reduction in the need for surgery or radiotherapy associated with Gleason grade progression versus controls. There was also a 65.4% decrease in the instances of surgery or radiotherapy, including elective cases without Gleason upgrades, in the 15-mg patient group.

The company noted that even though both doses were effective overall, the 15-mg dose worked better than the lower dose.

Nymox CEO Paul Averback said in the news release that the company has taken the first steps to meet with regulatory authorities regarding the planned registration trials for low grade prostate cancer.